Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2013-02-03 Capital/Financing Update
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
VGX-100 Phase 1 Clinical Trial Program Update 15 pages 1.1MB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release dated 4 February 2013 from Circadian Technologies Limited. It provides a detailed update on the VGX-100 Phase 1 clinical trial program in oncology, including trial design, interim clinical data, scientific rationale, and future plans. The text includes scientific and clinical trial information, but it is presented as a public announcement or update rather than a formal financial or regulatory report. There is no indication that this is a full financial report, earnings release, or regulatory filing. The document is lengthy (15,000 characters) and contains detailed information about clinical trial progress and scientific data, typical of a capital/financing update or clinical trial progress announcement. Given the content focuses on clinical trial updates and development progress, and it is an official company announcement, the best fitting category is Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, and often includes clinical trial progress updates relevant to investors. It is not a financial report or earnings release, nor a regulatory filing or management report. Therefore, the classification is CAP with high confidence.
2013-02-03 English
Company Presentation at JP Morgan Biotech Showcase 54 pages 3.3MB
Regulatory Filings
2013-01-09 English
Change of Director's Interest Notice 3 pages 76.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and other related information. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, management discussion, or regulatory certifications. The document length is about 4000 characters, which is typical for such notices. Therefore, the appropriate classification is Director's Dealing (DIRS).
2012-12-16 English
Open Briefing - CEO on Business Separation 2 pages 217.0KB
Call Transcript Classification · 95% confidence The document is an interview transcript with the CEO discussing business separation, subsidiary creation, investment strategy, and pipeline development. It is presented as an "Open Briefing" and includes detailed management commentary on company strategy and structure. There are no financial statements, quarterly or annual results, or audit information. The content is a detailed management discussion rather than a formal earnings release or annual report. It is not a regulatory filing or announcement of a report publication. The document fits best as a Call Transcript (CT) type, as it is a full text transcript of a company briefing/interview with management discussing business strategy and outlook.
2012-12-10 English
Appendix 3B 7 pages 127.0KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, issue price, purpose of the issue, and details related to quotation on the ASX (Australian Securities Exchange). It includes sections on the securities' ranking, underwriting, and quotation agreement with ASX. The document is a formal announcement of a new share issue and application for quotation of additional securities, consistent with regulatory requirements for capital raising disclosures. It does not contain financial statements, management discussion, or audit information, nor is it a report or presentation. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (9976 characters) is sufficient to be a full announcement rather than a brief notice or report publication announcement.
2012-11-20 English
Change of Director's Interest Notice 3 pages 77.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change, and consideration paid. This is a report of personal share transactions by a company director. The document length is 4026 characters, which is consistent with a detailed director's dealing notice. There is no indication that this is an annual report, earnings release, or any other type of financial or regulatory filing. Therefore, the document fits the definition of Director's Dealing (DIRS).
2012-11-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.